Prohost Letters
Premium
Prohost Letter #407
Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE BIOSCIENCES On March 27, a few days before the FDA approves Neurocrine’s (NBIX) drug Ingrezza, (valbe...
P
Prohost Biotech
1 min read
6
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Tags
AbbVie Inc (ABBV)
Amgen (AMGN)
Bellicum Pharmaceuticals Inc (BLCM)
Bristol-Myers Squibb (BMY)
CAR-T
Celyad (CYAD)
CytomX Therapeutics Inc (CTMX)
Illumina (ILMN)
ImmunoGen (IMGN)
Juno Therapeutics (JUNO)
Kite Pharma - A Gilead Company
MD Anderson
Neurocrine Biosciences (NBIX)
Novartis (NVS)
Pfizer (PFE)
Prohost Portfolio
Comments (0)
Please sign in to join the discussion